USP General Chapter <800> exists to protect healthcare workers from occupational exposure to hazardous drugs. Drug diversion prevention exists to protect patients and the public from the consequences of controlled substances leaving the legal distribution chain. In oncology pharmacies and other settings where hazardous drugs and controlled substances intersect, these two bodies of requirements overlap in ways that are underappreciated — and that create both shared risk and shared opportunity for control.

What USP 800 Requires

USP General Chapter <800>, Hazardous Drugs — Handling in Healthcare Settings, became official December 1, 2019. It applies to all healthcare personnel who handle hazardous drugs (HDs): pharmacists, pharmacy technicians, nurses, physicians, and environmental services staff. The chapter does not distinguish between settings — it applies in hospital pharmacies, outpatient infusion centers, retail pharmacies that compound, physician offices, and home health organizations.

A drug is considered hazardous under the NIOSH framework if it exhibits one or more of the following characteristics: carcinogenicity, teratogenicity or developmental toxicity, reproductive toxicity, organ toxicity at low doses, genotoxicity, or a structure and toxicity profile that mimics an existing hazardous drug. The National Institute for Occupational Safety and Health (NIOSH) publishes and updates the list of hazardous drugs; the current list is the authoritative reference for determining whether a drug falls under <800> requirements.

The physical requirements of USP <800> center on containment engineering controls. A containment primary engineering control (C-PEC) used for sterile HD compounding must provide ISO Class 5 air quality and must be externally vented — meaning the air exhausted from the C-PEC cannot be recirculated into the room. The containment secondary engineering control (C-SEC) — the room housing the C-PEC — must maintain ISO Class 7 air quality (if it is classified as a buffer room) or meet the requirements for an unclassified containment segregated compounding area (C-SCA). In either case, the C-SEC must maintain negative pressure relative to surrounding areas, so that any airborne contamination flows inward rather than out into the pharmacy or patient areas.

Closed-system transfer devices (CSTDs) are required when compounding or administering HDs that are not final dosage forms and when the route of administration allows use of a CSTD. CSTDs mechanically prevent the escape of drug or vapor during transfer and are a primary engineering control for exposure reduction. Personnel must wear two pairs of chemotherapy gloves when compounding or administering HDs — the outer pair must meet ASTM D6978 standard for chemotherapy resistance. A medical surveillance program must be in place to monitor personnel who are potentially exposed to HDs, with baseline and periodic health assessments documented.

Where Hazardous Drugs and Controlled Substances Overlap

Most hazardous drugs are not controlled substances, and most controlled substances are not hazardous drugs. The NIOSH hazardous drug list is dominated by antineoplastic agents, antiviral drugs, and reproductive hazards — classes that have little overlap with the DEA schedules. Only a small number of controlled substances also appear on the NIOSH hazardous drug list. That small overlap, however, is precisely where safe-handling requirements and diversion prevention controls must work together.

Certain opioids appear on the NIOSH list not because they are antineoplastic but because of reproductive toxicity or other hazard characteristics. When a facility handles a drug that is both a Schedule II controlled substance and a NIOSH hazardous drug, every transaction involving that drug must satisfy both frameworks simultaneously: the DEA accountability requirements (dispense records, waste documentation, inventory reconciliation) and the USP <800> handling requirements (C-PEC, CSTD, double gloves, negative pressure environment). These requirements are compatible and largely complementary — but they require coordination between the compliance function and the pharmacy operations team.

Beyond the direct overlap, oncology pharmacies routinely handle Schedule II and III controlled substances for pain management alongside their hazardous drug formulary. An infusion center that administers chemotherapy agents in the morning may administer opioid infusions in the afternoon, using the same staff, the same documentation systems, and the same physical space. The diversion risk associated with the opioids does not diminish because the setting is primarily focused on oncology. In some respects it is elevated, because the clinical complexity of the patient population and the volume of drug transactions can make anomalies harder to detect without deliberate surveillance.

How USP 800 Controls Strengthen the Diversion Audit Trail

One of the underappreciated benefits of USP <800> compliance in an oncology setting is that the documentation requirements it imposes on hazardous drug handling create a detailed, contemporaneous audit trail that supports diversion detection for controlled substances handled in the same environment.

CSTD use creates a closed, measurable system. When a CSTD is used to transfer drug from a vial to a bag or syringe, the mechanical closure of the system means that drug can only move through documented connections. Residual drug remaining in a vial after transfer is observable and quantifiable. If the amount transferred plus the amount of waste does not equal the amount drawn from the vial, there is an unexplained gap. For controlled substances, that gap is a diversion red flag; for hazardous drugs, it is also a spill or loss that should be documented. In both cases, the CSTD makes the discrepancy visible in a way that open-system transfer does not.

Two-pair glove requirements create a witnessed workflow. The requirement that two people be present — one to compound and one to witness the double-glove removal process — is not a diversion control, but it has diversion-deterrent effects. Compounding in isolation is harder to sustain in a setting where USP <800> requires observed technique verification. Pharmacy leaders should recognize that the staffing model required for <800> compliance also reduces the single-person access risk that is central to IV room diversion.

Negative pressure and access logs create a physical control boundary. The C-SEC's requirement for negative pressure and restricted access means that access events to the compounding area are inherently logged when electronic badge access is used. Those access logs, reviewed alongside dispense records and waste documentation, provide a record of who was in the compounding area at what time — the same data that a diversion investigation would need to establish opportunity.

Diversion Red Flags Specific to Oncology and HD Settings

The diversion risk profile in an oncology pharmacy or infusion center has features that differ from a general acute care or retail setting. Recognizing these differences allows surveillance to be calibrated appropriately.

  • High-volume preparation schedules obscure individual dose accountability. An infusion center that prepares dozens of chemotherapy doses per day also prepares and administers multiple opioid infusions. The volume of drug transactions — including the volume of waste events — can make it difficult to detect individual discrepancies without systematic reconciliation. High-volume environments require automated or structured reconciliation rather than relying on manual review to catch anomalies.
  • Residual drug in CSTDs is a diversion opportunity. After preparation or administration, a CSTD may retain residual drug in its internal passages. For non-controlled hazardous drugs, this residual is an exposure hazard. For controlled substances, it is also an accountability question: where does that residual go, and how is it documented? CSTD-specific waste documentation procedures should address controlled substance residual explicitly.
  • Patient-specific preparation reduces surplus drug visibility. In oncology, preparations are frequently patient-specific and weight-based, meaning the dose prepared should be close to the dose administered. When a dose is prepared and then not administered — because the patient's treatment was delayed or the dose was rejected on quality review — the disposition of that preparation must be documented. Controlled substance preparations that are prepared but not administered are a common gap in oncology diversion documentation.
  • Nurse-administered opioids in infusion settings carry the same risks as in acute care. Opioid medications administered to oncology patients in an infusion center are subject to the same diversion patterns as opioids administered in a hospital: waste that is not witnessed, returned doses that are not reconciled, and override patterns that deviate from peer norms. Infusion center diversion surveillance should include administration-side waste and override review, not only pharmacy-side preparation records.
  • Oncology dispensing pattern anomalies. As with any controlled substance, dispensing patterns for controlled substances handled in the oncology setting should be reviewed for anomalies: outliers by prescriber, by patient, by technician, or by time of day. Benchmark oncology opioid dispense volumes against facility baseline and peer facilities where data is available.

Program Controls for HD Settings with Controlled Substances

Secure storage and inventory of all controlled HDs. Any drug that is both a DEA-scheduled controlled substance and a NIOSH hazardous drug must satisfy the storage requirements of both frameworks. DEA requires storage in a securely locked, substantially constructed cabinet. USP <800> requires storage in a containment area with appropriate ventilation if the drug is volatile or aerosolizable. In most cases these requirements can be met simultaneously, but the design of the storage area must be reviewed against both standards. Inventory counts for controlled HDs must follow the DEA counting requirements — exact count for Schedule II, exact count for opened Schedule III–V containers — and must be reconciled against transaction records on the same schedule as other controlled substances.

Unified waste documentation for controlled substance HDs. When a drug is both hazardous and controlled, waste documentation must satisfy both the witnessed waste requirement for controlled substances and the USP <800> requirement for documentation of HD waste events. A single waste record that captures the drug name, lot number, quantity wasted, disposal method, witness identity, and time satisfies both requirements. Facilities that maintain separate quality and compliance waste records for the same drug should consolidate them — dual documentation creates reconciliation gaps rather than closing them.

Surveillance that spans the pharmacy-to-administration continuum. Effective oncology diversion surveillance cannot stop at the compounding window. The same dose that was prepared under USP <800> controls must be tracked through dispensing and to the administration event recorded in the medication administration record. Reconciling preparation, dispense, and administration records for controlled substances — including those that are also hazardous drugs — is the core of an oncology-specific diversion detection program.

Medical surveillance data as a secondary indicator. The medical surveillance program required by USP <800> monitors personnel for biological evidence of HD exposure — urinary metabolites, blood levels, and other markers depending on the drug. While medical surveillance is designed to detect unintentional exposure, results that are inconsistent with a staff member's documented work assignments or protective equipment compliance may warrant review in the context of a broader diversion investigation. Medical surveillance data is protected health information and must be handled accordingly; consult with your legal and HR team before any cross-referencing with compliance investigations.

Building an Integrated Compliance Posture

Facilities that treat USP <800> compliance and controlled substance diversion prevention as separate programs — separate policies, separate documentation, separate oversight functions — create gaps that a motivated individual can exploit. The physical controls, documentation requirements, and personnel procedures of <800> are largely complementary to the accountability controls required for controlled substance diversion prevention. The integration work is primarily organizational: ensuring that the pharmacy quality team and the compliance team share data, that audit findings are reviewed jointly, and that policy gaps identified in one framework are evaluated for implications in the other.

For a comprehensive view of where your oncology or infusion center pharmacy program stands, use the hospital pharmacy diversion prevention checklist, which includes controls relevant to high-risk settings. The 15 red flags page covers the behavioral and transactional indicators that complement the engineering and documentation controls described here. If your surveillance has identified a potential significant loss, the DEA Form 106 guide and the tough issues page provide guidance on the reporting threshold determination.